| Project/Area Number |
24659801
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Emergency medicine
|
|---|
| Research Institution | Keio University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YAMADA Takashige 慶應義塾大学, 医学部, 共同研究院 (20348767)
|
|---|
| Project Period (FY) |
2012-04-01 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | 感染症 / NGAL / 静菌効果 / lipocalin-2 / bacteria / infection |
|---|
| Research Abstract |
We previously focused on bacteriostatic effects of neutrophil gelatinase-associated lipocalin (NGAL), known as a biomarker of acute kidney injury, and investigated the interaction between this protein and intestinal microflora. The present study demonstrated that bacteriostatic effects of NGAL against bacteria, which is frequently found in clinical situations. As a result, gram-negative bacteria such as Escherichia coli, Klebsiella pneumoniae and Enterobacter cloacae was investigated to examine the bacteriostatic effects of NGAL in vitro. To detect bacterial growth, real-time PCR by using bacteria specific primer was performed. Although 1 mcg NGAL did not prevent the growth of these bacteria in vitro, 15 mcg NGAL tended to inhibit the growth of Escherichia coli, but it did not reach statistically significance. In conclusion, the present study demonstrated that high concentration NGAL might be able to inhibit the growth of Escherichia coli.
|
